S1. ORR by platinum-sensitivity in ovarian cancer patients treated with fluzoparib ≥120 mg/d.

Platinum-based therapy	End point	120 mg qd	60 mg bid	160 mg qd	80 mg bid	100 mg bid	150 mg bid	200 mg bid	Total
ORR, objective response rate.
First line platinum-sensitive and last course platinum-sensitive	Total subjects (N)	1	1	0	1	6	2	0	11
	Efficacy evaluable subjects (n)	1	1	0	1	5	2	0	10
	ORR based on total subjects [n (%)]	1 (100)	1 (100)	0	0	1 (16.7)	0	0	3 (27.3)
	ORR based on efficacy evaluable subjects [n (%)]	1 (100)	1 (100)	0	0	1 (20.0)	0	0	3 (30.0)
First line platinum-sensitive and last course platinum resistant	Total subjects (N)	0	0	1	4	0	4	1	10
	Efficacy evaluable subjects (n)	0	0	1	3	0	3	1	8
	ORR based on total subjects [n (%)]	0	0	0	0	0	0	0	0
	ORR based on efficacy evaluable subjects [n (%)]	0	0	0	0	0	0	0	0
First line platinum-sensitive and last course platinum refractory	Total subjects (N)	0	1	0	2	4	2	0	9
	Efficacy evaluable subjects (n)	0	1	0	2	4	2	0	9
	ORR based on total subjects [n (%)]	0	0	0	0	0	0	0	0
	ORR based on efficacy evaluable subjects [n (%)]	0	0	0	0	0	0	0	0
First line platinum-resistant or refractory	Total subjects (N)	0	0	0	4	2	6	1	13
	Efficacy evaluable subjects (n)	0	0	0	2	2	3	1	8
	ORR based on total subjects [n (%)]	0	0	0	0	0	0	0	0
	ORR based on efficacy evaluable subjects [n (%)]	0	0	0	0	0	0	0	0